The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
A | Alimentary tract and metabolism | |
2
|
A02 | Drugs for acid related disorders | |
3
|
A02B | DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) | |
4
|
A02BC | Proton pump inhibitors | |
5
|
A02BC04 | Rabeprazole |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 20 mg |
| Active Ingredient |
|---|
|
Rabeprazole belongs to the class of anti-secretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonist properties, but suppress gastric acid secretion by the specific inhibition of the H+/K+ -ATPase enzyme (the acid or proton pump). |
| Document | Type | Information Source | |
|---|---|---|---|
| ACIPHEX Delayed-release tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| ACIPHEX SPRINKLE Delayed-release capsule | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| PARIET Gastro-resistant tablet | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| RAZOLE Gastro-resistant tablet | MPI, EU: SmPC | Health Products Regulatory Authority (IE) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.